News Related to QRX003

Related coverage linked through entity extraction aliases.

Quoin Pharmaceuticals Secures Key Regulatory Designations and Reports Clinical Progress

Mar 26, 2026

Quoin Pharmaceuticals has secured Orphan Drug Designations for QRX003 in the U.S. and Europe for Netherton Syndrome, while advancing regulatory pathways in Japan and Saudi Arabia. The company reported clinical progress including expansion of pediatric studies and potential for a Priority Review Voucher worth up to $200 million.

FDA Grants Fast Track Designation to Multiple Therapies for Rare Diseases and Hematologic Malignancies

Mar 11, 2026

The FDA has granted fast track designation to QRX003 for Netherton Syndrome and IBI3003 for relapsed or refractory multiple myeloma, while also accepting regulatory applications for other therapies addressing serious conditions with unmet medical needs.